136 related articles for article (PubMed ID: 10206466)
1. Delayed methotrexate clearance in a patient with sickle cell anemia and osteosarcoma.
Mantadakis E; Rogers ZR; Smith AK; Quigley R; Ratliff AF; Kamen BA
J Pediatr Hematol Oncol; 1999; 21(2):165-9. PubMed ID: 10206466
[TBL] [Abstract][Full Text] [Related]
2. Clearance of methotrexate by means of hemofiltration in a patient with osteosarcoma.
Escobosa Sánchez OM; Herrero Hernández A; Ortega Acosta MJ; Camacho Alonso J; Milano Manso G; Acha García T
Clin Transl Oncol; 2006 May; 8(5):379-80. PubMed ID: 16760016
[No Abstract] [Full Text] [Related]
3. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
[TBL] [Abstract][Full Text] [Related]
4. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.
Widemann BC; Balis FM; Kempf-Bielack B; Bielack S; Pratt CB; Ferrari S; Bacci G; Craft AW; Adamson PC
Cancer; 2004 May; 100(10):2222-32. PubMed ID: 15139068
[TBL] [Abstract][Full Text] [Related]
5. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin.
Bacci G; Picci P; Ferrari S; Ruggieri P; Casadei R; Tienghi A; Brach del Prever A; Gherlinzoni F; Mercuri M; Monti C
Cancer; 1993 Dec; 72(11):3227-38. PubMed ID: 8242546
[TBL] [Abstract][Full Text] [Related]
6. An opinion supporting the role of high-dose methotrexate in the treatment of osteosarcoma.
Rosen G
Cancer Treat Res; 1993; 62():49-54. PubMed ID: 8096759
[No Abstract] [Full Text] [Related]
7. Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).
Shkalim-Zemer V; Ash S; Toledano H; Kollender Y; Issakov J; Yaniv I; Cohen IJ
Cancer Chemother Pharmacol; 2015 Nov; 76(5):909-16. PubMed ID: 26365289
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy.
Widemann BC; Schwartz S; Jayaprakash N; Christensen R; Pui CH; Chauhan N; Daugherty C; King TR; Rush JE; Howard SC
Pharmacotherapy; 2014 May; 34(5):427-39. PubMed ID: 24132809
[TBL] [Abstract][Full Text] [Related]
9. Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.
Nowicki TS; Bjornard K; Kudlowitz D; Sandoval C; Jayabose S
J Pediatr Hematol Oncol; 2008 Dec; 30(12):950-2. PubMed ID: 19131789
[TBL] [Abstract][Full Text] [Related]
10. [The effect of methotrexate pharmacokinetics and of leucovorin rescue on the prognosis of osteosarcoma].
Graf N; Jost W; Müller J; Keller HE; Sitzmann FC
Klin Padiatr; 1990; 202(5):340-6. PubMed ID: 2214594
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of l-leucovorin rescue following high-dose methotrexate for osteosarcoma.
Goorin A; Strother D; Poplack D; Letvak LA; George M; Link M
Med Pediatr Oncol; 1995 Jun; 24(6):362-7. PubMed ID: 7715542
[TBL] [Abstract][Full Text] [Related]
12. Cerebral arterial disturbances in a transient encephalopathy induced by methotrexate.
Follezou JY; Chauveinc L; Guerin JM
Med Oncol Tumor Pharmacother; 1993; 10(4):181-3. PubMed ID: 8164455
[TBL] [Abstract][Full Text] [Related]
13. Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity.
Widemann BC; Hetherington ML; Murphy RF; Balis FM; Adamson PC
Cancer; 1995 Aug; 76(3):521-6. PubMed ID: 8625136
[TBL] [Abstract][Full Text] [Related]
14. Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients.
Scott JR; Zhou Y; Cheng C; Ward DA; Swanson HD; Molinelli AR; Stewart CF; Navid F; Jeha S; Relling MV; Crews KR
Pediatr Blood Cancer; 2015 Sep; 62(9):1518-22. PubMed ID: 25631103
[TBL] [Abstract][Full Text] [Related]
15. Disposition of high-dose methotrexate in an obese cancer patient.
Fleming RA; Eldridge RM; Johnson CE; Stewart CF
Cancer; 1991 Sep; 68(6):1247-50. PubMed ID: 1714790
[TBL] [Abstract][Full Text] [Related]
16. Progression of osteosarcoma after high-dose methotrexate: over-rescue by folinic acid.
Cohen IJ
Pediatr Hematol Oncol; 2003 Dec; 20(8):579-81. PubMed ID: 14578026
[TBL] [Abstract][Full Text] [Related]
17. Osteosarcoma of the limb: an institutional report of 10 years experience with neoadjuvant chemotherapy and delayed surgery.
Postma A; Kamps WA; Schraffordt Koops H; Veth RP; Göeken LN; Molenaar WM
Cancer Treat Res; 1993; 62():361-4. PubMed ID: 7682095
[No Abstract] [Full Text] [Related]
18. Neoadjuvant high-dose methotrexate, cisplatin, and doxorubicin for the management of patients with nonmetastatic osteosarcoma.
Weiner MA; Harris MB; Lewis M; Jones R; Sherry H; Feurer EJ; Johnson J; Lahman E
Cancer Treat Rep; 1986 Dec; 70(12):1431-2. PubMed ID: 3466693
[No Abstract] [Full Text] [Related]
19. Substitution of l-leucovorin for d,l-leucovorin in the rescue from high-dose methotrexate treatment in patients with osteosarcoma.
Jaffe N; Jorgensen K; Robertson R; George M; Letvak L; Barrett G
Anticancer Drugs; 1993 Oct; 4(5):559-64. PubMed ID: 8292813
[TBL] [Abstract][Full Text] [Related]
20. An update of Scandinavian studies of osteosarcoma.
Elomaa I
Cancer Treat Res; 1993; 62():293-8. PubMed ID: 8096745
[No Abstract] [Full Text] [Related]
[Next] [New Search]
